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INTRODUCTION
Since the discovery by Alexander Fleming of penicillin in 1929 and the subsequent 
journey of antibiotic research and discovery, antibiotics have revolutionized human 
health on a global scale. Antibiotic therapy can be acknowledged for a significant 
increase in life expectancy between 1944 and 1972, a period of intensive and success-
ful antibiotic research (Cotter et al., 2012). However, the negative effects of antibiotic 
therapy are well documented, most notably antimicrobial resistance, which is now 
accepted as a global issue spanning medical, economic, and environmental fronts. 
The World Health Organization, Centers for Disease Control and Prevention (CDC), 
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and European Center for Disease Prevention and Control consider multidrug-resistant 
(MDR) infections caused by antibiotic-resistant bacteria as an emergent global dis-
ease and a major threat to public health (Roca et al., 2015). However, this review 
will focus on the more pervasive effects of antibiotic therapy on the gut microbiome 
and the far-reaching effects on the health of the host. The antibiotic-mediated per-
turbations of the microbiome and disruption of related functionality is an area of 
much research. In recent years the collateral damage caused by antibiotic use has 
come into focus (Blaser, 2011). Antibiotic therapy can be likened to a war of attri-
tion on the gut microbiota because subsequent rounds of therapy result in loss of 
diversity followed by incomplete recovery causing the bacterial population to shift 
from the initial assemblage. The control of infection through antibiotic use, while not 
diminishing its importance, has potentially devastating consequences downstream 
not only for the individual, as host-microbe interactions are disturbed, but also for 
society with the potential dissemination of MDR determinants. In this review we 
examine the literature regarding the effects of various families of antibiotics on the 
gut microbiota, discussing in particular issues with relevance to a cystic fibrosis (CF) 
cohort, such as MDR as a result of chronic antibiotic use, Clostridium difficile, and 
disruption of host-microbiota mutualistic relationships.
Perturbations of the gut microbiota can occur via many external environmental fac-
tors, but perhaps the most dramatic modulatory effects are seen with antibiotic use. The 
immediate impact of short-term antibiotic therapy on the gut microbiota is extensively 
investigated. However, longitudinal studies mapping the recovery of the microbiota 
in the aftermath are limited, with even greater gaps in our knowledge regarding the 
long-term effects of chronic antibiotic use on the gut microbiota. Studies focusing on 
short-term antibiotic use have demonstrated the profound and pervasive effects of the 
antibiotic, the resilience of the gut microbiota after treatment (Dethlefsen et al., 2008; 
Jernberg et al., 2007), and reduction of fecal bacterial load and diversity (Xu et al., 
2014; Iapichino et al., 2008; Jakobsson et al., 2010). Others have demonstrated the 
differential effects of different classes of antibiotics on the gut microbiota and how 
the resultant assembly after antibiotic treatment may be influenced by mode of action 
(Perez-Cobas et al., 2013). It is widely reported that immediately after antibiotic treat-
ment an increase in Enterococcus species (Iapichino et al., 2008) and a decrease in 
Bifidobacteria, Clostridia, Desulfovibrio, Faecalibacterium and Bacteroides species 
(Adamsson et al., 1999; Bartosch et al., 2004; Jernberg et al., 2007; O’Sullivan et al., 
2013) is expected. Most microbiota recover after 4 weeks; however, a long-term per-
sistence of expressed antibiotic resistance genes, particularly carried by Enterococcus 
species, after a short-term antibiotic treatment was noted up to 4 years posttreatment in 
some human studies (Jakobsson et al., 2010; Jernberg et al., 2007).
CF cohorts are ideal candidate groups to investigate the effects of antibiotic use 
on gut health and microbiota. CF is a monogenic disorder, thereby reducing con-
founding factors and so facilitating inferences regarding antibiotic effects on the gut 
microbiota. CF is a potentially life-threatening autosomal-recessive disorder affect-
ing 70,000 individuals worldwide, with Ireland having the highest prevalence (∼1100 
patients) and incidence rates (1 in 1353; Farrell, 2008). It results from mutations in 
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the cystic fibrosis transmembrane conductance regulator (CFTR) gene, located on 
the long arm of chromosome 7 (Collins, 1992), of which the most common is ΔF508 
(a deletion of phenylalanine at codon 508). CFTR gene mutations result in defective 
chloride ion transport in the respiratory, hepatobiliary, gastrointestinal, reproductive 
tracts, and the pancreas (Quinton, 1990). The natural progression of CF is character-
ized by chronic lung function decline punctuated by recurrent periods of temporary 
worsening of symptoms, known as pulmonary exacerbations (Amadori et al., 2009; 
Flume et al., 2009). Prophylactic antibiotic therapy plays a pivotal role in treating 
CF patients; combating frequent lung infections, slowing the rate of lung function 
decline, and ultimately prolonging life. Indeed antibiotic discovery, amongst other 
therapeutic options, has significantly contributed to the increased life expectancy 
of CF sufferers, meaning many survive into their thirties and beyond whereas in 
the 1950s few lived to attend primary school. The increasing life expectancy of 
CF individuals presents further new therapeutic challenges (Plant et al., 2013). A 
global shifting pattern of antibiotic use is seen in antibiotic therapy for CF patients in 
which prophylaxis, maintenance, and chronic antibiotic therapy have been shown to 
improve clinical outcomes and survival (Moskowitz et al., 2008; Szaff et al., 1983).
Although the gut microbiota of CF patients is poorly documented, it can be assumed 
that intensive and frequent courses of antibiotics alter its diversity and function as a 
symbiotic partner with the host. Seventy percent of the immune system is harbored 
in the gastrointestinal tract, meaning perturbations in the microbiome at the very least 
will have implications for host immunity, but also for energy extraction efficiency from 
food, mental well-being, and colonization resistance against pathogenic microorgan-
isms (Weiner, 2000; Faria and Weiner, 2005; Vighi et al., 2008). Defining and charac-
terizing the gut microbiota of a CF population can provide information applicable to the 
wider medical community. A picture of the gut microbiota of CF patients as a unique 
entity that is a signature of the disease is emerging in recent research. The character-
istic CF intestinal microbiome is thought to be as a result of a combination of factors 
including the CFTR malfunction itself, chronic antibiotic use, high-fat diet, pancreatic 
enzyme supplementation, and suppression of gastric acid (Bruzzese et al., 2014). The 
CF gut has been shown to have lower counts of lactic acid bacteria (LAB), Clostridium 
species, Bifidobacterium species, Veillonella species, and Bacteroides-Prevotella spe-
cies, whereas Enterobacteriaceae counts were increased in the CF cohort (Duytchaever 
et al., 2011). As expected in a cohort with chronic antibiotic use, CF patients have been 
shown to have lower species richness, evenness, diversity, and reduced temporal stabil-
ity of intestinal microbiota (Scanlan et al., 2012). In particular, the reduction of diversity 
and abundance of Bifidobacterium species (Bifidobacterium longum, Bifidobacterium 
catenulatum, Bifidobacterium pseudocatenulatum, and Bifidobacterium adolescentis), 
Clostridium cluster XIVa, and Clostridium cluster IV (R. bromii and Faecalibacterium 
prausnitzii) has been described (Duytschaever et al., 2013). Bifidobacterium species 
have a greater antimicrobial susceptibility to many antibiotics used in the treatment 
of CF pulmonary exacerbations and reduced adhesion capacity to inflamed mucosa 
(Lee and O’Sullivan, 2010; Russell et al., 2011), perhaps explaining their reduction in 
a CF cohort. Evidence from Madan et al. (2012) revealed a core lung-gut microbiota 
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dominated by Veillonella and Streptococcus, with similarities between population fluc-
tuations between the two sites. Furthermore, they show that select genera (Roseburia, 
Dorea, Sporacetigenium, Coprococcus, Blautia, Enterococcus, and Escherichia) of 
the gut microbiota precede bacterial populations found in the lung. Allelic variations of 
the CFTR gene have also been shown to have effects on the gut microbiota, with homo-
zygous F508del and severe disease phenotype CF patients exhibiting greater dysbiotic 
fecal microbiota compared with heterozygous milder disease phenotype patients, a 
signature most likely reflective of reduced therapies (Schippa et al., 2013). It is hypoth-
esized that imbalance of the intestinal microbiota of CF patients may be associated 
with causes, or aids, the progression of the disease and may be a predictor of expected 
outcomes after antibiotic therapy (Duytschaever et al., 2011).
ANTIBIOTICS USE AMONG PERSONS WITH CYSTIC FIBROSIS
Antibiotic regimens for CF patients currently follow one of the following strategies: a 
symptomatic regimen that is treatment of pulmonary exacerbation upon notice of acute 
symptoms (Elphick and Tan, 2005) or elective regimens that may comprise treatment 
of the chronic infection with intravenous, inhaled, and/or oral antibiotics at regular 
intervals to delay or prevent long-term deterioration in the absence of recent clinical 
deterioration (Høiby, 1993; Moskowitz et al., 2008). The latter elective regimens 
constitute chronic antibiotic usage or prophylaxis and have become routine practice 
to prevent or delay pulmonary exacerbations. CF patients typically undergo antibi-
otic treatment involving a combination of inhaled and oral therapies as well as poten-
tially intravenous treatments from different mechanistic classes (eg, ceftazidime and 
tobramycin; Smyth et al., 2014; Flume et al., 2009). With the advent of efficient 
nebulization devices in the 1990s, inhaled antibiotics became the mainstay in CF 
therapy maintenance, enabling eradication of initial Pseudomonas infection (Ramsey 
et al., 1999; Pamukcu et al., 1995; Wall et al., 1983; Moskowitz et al., 2008; Gibson 
et al., 2003). Inhaled antibiotics result in greater concentrations arriving directly to 
the respiratory system secretions, local to the infection (Moskowitz et al., 2008). 
Nebulized/inhaled tobramycin, aztreonam, and colistin form the main therapeutic 
options for eradication and/or suppression of Pseudomonas aeruginosa in the lung 
(Döring et al., 2012). Nebulization duration is associated with a significant treatment 
burden on the patient and may result in poorer clinical outcomes because of reduced 
compliance with the treatment regimen (Sawicki and Tiddens, 2012). Advances in 
addressing patient treatment burden are seen with the emergence of portable dry 
powder formulations of tobramycin (TOBI podhaler) and colistimethate sodium 
(Colobreathe; Konstan et al., 2011; Schuster et al., 2013; Uttley et al., 2013). Rapid 
delivery systems for antibiotic therapies via portable inhalers significantly reduce 
treatment burden and increase adherence (Harrison et al., 2014).
The success of a particular antibiotic treatment regimen is assessed primarily by 
considering its efficacy at suppression or eradication of the infectious agents and 
subsequent improvement in lung function, measured as FEV1 (Forced Expiratory 
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Volume in the first second). In addition to the need for hospitalization, the length 
of time until the requirement for additional antibiotics, the time to reoccurrence of 
pulmonary exacerbation, the number and severity of adverse events experienced by 
patients, and the convenience and patient satisfaction (hence ease of compliance) for 
the patient are factors considered.
THE MODULATORY EFFECTS OF SPECIFIC ANTIBIOTICS ON THE GUT 
MICROBIOTA (NON-CYSTIC FIBROSIS HOSTS)
The human gut microbiota is individual specific at the bacterial strain level (Turnbaugh 
and Gordon, 2009; Lozupone et al., 2012; Schloissnig et al., 2013). How antibiotic 
therapies interact and perturb the microbiota varies between individuals, with individu-
als on the same antibiotic, dose, and time showing varying effects, albeit similar trends 
(Perez-Cobas et al., 2013). Dethlefsen et al. (2008) showed not only interindividual 
variation in response to ciprofloxacin but also different responses of taxa. Grouping of 
metagenomic data from several individuals may mask individual perturbations. There-
fore it is preferable to measure distance from baseline in each individual to reveal the 
true effect of the antibiotic treatment (Engelbrektson et al., 2006). Diet, genetics, and 
health status as well as the dynamics of the microbiota itself may contribute to stability 
within the intestinal microbiota, enabling some communities to have more resilience 
than others in response to antibiotic therapy (Perez-Cobas et al., 2013). This elaborate 
network fed by numerous variables presents a huge challenge when analyzing micro-
biota responses to antibiotic treatment. Countering the effect of the antibiotic is the 
resilience and stability of the microbiota. The balance of the microbiota to external 
pressures is mediated by host–microbe interactions, microbe–microbe interactions, 
and physiochemical factors (Edlund et al., 2000).
The effects of antibiotics on the gut microbiome are unique to each antibiotic 
and depend on several factors: the target spectra, the dose and duration, the method 
of administration and the pharmacokinetic and pharmacodynamic properties of the 
agent (incomplete absorption or secretion of intravenous antibiotics by bile or intes-
tinal mucosa may result in higher concentrations in the intestine with greater eco-
logical effects; Edlund et al., 2000; Jernberg et al., 2010; Adamsson et al., 1999). 
Disturbances may be assessed (1) qualitatively (emergence of novel bacteria types 
with resistance genes, plasmids, and transposons) or (2) quantitatively (changes in 
microbiota composition due to antibiotic pressures; Edlund et al., 2000). Broad- 
spectrum antibiotic treatments affect not only the aberrant pathogenic bacteria but 
also beneficial members of the gut community, reduce diversity and richness, and 
disturb the ecology of the gut (Jernberg et al., 2007; Dethlefsen and Relman, 2011; 
O’ Sullivan et al., 2012). However, it remains a challenge to distinguish antibiotic 
effects on the gut microbiota from other confounding factors such as stress, diet and 
host genetics (Jernberg et al., 2010). The route of administration has implications for 
antibiotic-mediated disturbances in the gut microbiota because oral, inhaled and intra-
venous routes result in different concentrations in different sites (Liu and Derendorf, 
2003; Liu et al., 2002).
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The gut microbiota has a degree of resilience to antibiotic treatment, the strength 
of which may vary depending on which microorganisms form a given individual’s 
microbiota, some conferring more stability than others. Recovery of gut microbiota 
is often rapid, ranging from 2 days (Dethlefsen and Relman, 2011) to 2 weeks (Ubeda 
et al., 2010); however, individual taxa have different recovery rates, some slower than 
others as seen with increased proportions of Lachnospiracaea and Clostridiacaea 
by Antonopoulos and colleagues (2009) 6 weeks posttreatment with cefoperazone. 
For many, recovery is often incomplete or partial (Dethlefsen and Relman, 2011). 
This resilience may be apparent in the first round of therapy, and it is in subsequent, 
repetitive or prolonged rounds of therapy that shifts in the microbiota may be seen 
(Perez-Cobas et al., 2013). The magnitude and rate of the response is primarily dic-
tated by the initial microbial community, with some communities displaying a pro-
longed directional shift and others a more rapid response (Dethlefsen and Relman, 
2011). Initial community composition could be an important indication of expected 
outcomes after antibiotic use, such as likelihood of pathogen overgrowth or develop-
ment of antibiotic-associated diarrhea (AAD; De La Cochetiere et al., 2008; Ozaki 
et al., 2004). Although the gut microbiota is stable, it is never static. Its periodic 
variations within a normal range make it difficult to definitively attribute loss or 
gain of certain taxa to certain antibiotics. Dethlefsen and Relman (2011) explain 
that the long-term stability of the gut microbiota is maintained by restoring forces 
after external disturbances rather than rigidity or resistance to change. However, the 
restoring forces will not withstand repeated antibiotic courses, even in cases in which 
the microbiota has completely recovered after an initial antibiotic treatment.
Antibiotics families vary in mode of action and target specificity and therefore in 
the fingerprint they leave on the gut microbiota. Perez-Cobas et al. (2013) showed 
that the greatest influence on the microbiota is the antimicrobial effect and the mode 
of antibiotic action. At the compositional level, the mode of action exerts the great-
est effect, although at the functional level the antimicrobial effect is the driving force 
(Perez-Cobas et al., 2013). The mode of action of the antimicrobial agent produces 
different effects on the gut community. O’Sullivan et al. (2013) noted a significantly 
greater reduction of Bifidobacterium species and significant differences in levels of 
Anaerococcus, Denitrobacterium, Faecalibacterium, Lactonifactor, and Proteus spe-
cies in subjects receiving only a nucleic acid inhibitor compared with subjects on 
antibiotics with cell envelope mode of action, whereas subjects receiving only cell 
envelope antibiotics had significantly increased levels (10-fold) of Lactobacillus spe-
cies and significant differences in levels of Ascomycota and Elusimicrobia. They con-
cluded that cell envelope inhibitors had less impact on the intestinal microbiota than 
nucleic acid synthesis inhibitors. The effects are taxa specific with some more suscep-
tible than others; however, signatures of antimicrobial classes can be seen in bacterial 
profiles after treatment, with individuals’ diverse microbiota converging to simi-
lar compositions when administered the same antibiotic (Perez-Cobas et al., 2013; 
Jernberg et al., 2010; Antonopoulos et al., 2009). The selection of antibiotic should 
be based not only on the expected success of the antibiotic treatment but also on the 
level of ecological disturbances (Edlund et al., 2000). There is a lack of information 
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detailing the effects of chronic usage of different antibiotic classes on the gut micro-
biota. Here we discuss the signatures produced by short-term use of different antibi-
otic classes, as shown in human studies, unless stated otherwise. See Table 11.1 for 
a summary of the effects of specific antibiotic classes on the intestinal microbiota.
Macrolides
Macrolides are so called because of their macrocyclic ring, which may be 14, 15, 
or 16 membered (Hamilton-Miller, 1992). They have a protein synthesis inhibitory 
mode of action. Macrolides have been shown to inhibit protein synthesis by caus-
ing a dissociation of the peptidyl-tRNA from the ribosome (Tenson et al., 2003). 
Azithromycin has been shown to significantly improve quality of life in CF patients, 
reduce C-reactive protein levels, reduce the rate of lung function decline (FEV1 mea-
surements), reduce the number of respiratory exacerbations, and significantly reduce 
systemic inflammation (Saiman et al., 2003; Wolter et al., 2002). Azithromycin is 
chosen for macrolide therapy over other macrolides, such as erythromycin, because 
of less adverse effects on the gastrointestinal tract. Azithromycin is also known to 
have negative effects on the bacterial motility of P. aeruginosa through suppression 
of flagellin expression at subinhibitory concentrations (Kawamura-Sato et al., 2000). 
In a study of three adults presenting with gastric and duodenal ulcers, Jakobsson 
et al. (2010) showed the negative impact of Clarithromycin on members of the Acti-
nobacteria phyla; significant reductions of Escherichia coli; suppression of Bifido-
bacterium, Lactobacillus, and Clostridium species; and an increase in Enterococcus, 
Enterobacter, Citrobacter, Klebsiella, and Pseudomonas species. Clarithromycin 
has been shown to strongly suppress anaerobic populations in a study of healthy 
adults comparing Clarithromycin to a fluoroquinolone, moxifloxacin-based treat-
ment regimen (Adamsson et al., 1999; Brismar et al., 1991; Edlund et al., 2000). 
This has important implications for total ecological disturbances because the anaero-
bic population is mainly responsible for colonization resistance (Waaij, 1989; Hertz 
et al., 2014). Adamsson et al. (1999) also showed a significant qualitative change 
with an increase of resistant Bacteroides from 2% to 76% in a study of 30 adults 
with Helicobacter pylori infection. This indicates an antibiotic class with the ability 
for ecological disruption and promotion of resistant strains. This contrasts with the 
findings of Morotomi et al. (2011), which show that macrolide antibiotic treatments 
tended toward dominance of Streptococcus species and seemed to have less dramatic 
effects on the microbiota with samples remaining similar to healthy intestinal micro-
biota in a study of 29 healthy adults (Morotomi et al., 2011).
β-Lactams
β-Lactams, encompassing cephalosporins, carbapenems, penicillins, monobactams, 
and cephamycins, are considered the most successful antibiotic class discovered 
(Lewis, 2013). β-Lactams form an important part of treatment of pulmonary exac-
erbation for CF patients. Ceftazidime, meropenem, flucloxacillin, piperacillin/taxo-
bactam, and aztreonam are all β-lactam therapies commonly used by CF patients. 
β-Lactams have a bactericidal mode of action that disrupts cell wall synthesis, 
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Table 11.1 Summary of the Effects of Specific Antibiotic Classes on the Intestinal Microbiota
Antibiotic Class
Specific 
Antibiotic 
Examples Mode of Action Gut Microbiota Effects References
Aminoglycosides Tobramycin Bactericidal agents that inhibit pro-
tein synthesis by binding the 30S 
prokaryotic subunit.
Little in literature. Bifidobacteria are known 
to have innate resistance due to lack of 
cytochrome-mediated transport  
mechanism for aminoglycoside uptake.
Bryan et al. (1979)
Macrolides Azithromycin, 
erythromycin, 
clarithromycin
Protein synthesis inhibitory mode of 
action by initiating a dissociation  
of the peptidyl-tRNA from the 
ribosome.
Clarithromycin has been shown to reduce 
Actinobacteria phyla, E. coli, bifidobacte-
ria, lactobacilli, clostridia, and anaerobic 
populations and increase enterococci, 
Enterobacter, Citrobacter, Klebsiella, 
Pseudomonas, and resistant Bacteroides.
Jakobsson et al. 
(2010)
Adamsson et al. 
(1999)
Brismar et al. (1991)
Edlund et al. (2000)
β-Lactams Penicillin, 
ceftazidime, 
meropenem, 
flucloxacillin, 
coamoxiclav, 
piperacillin/
tazobactam, 
aztreonam
Bactericidal mode of action,  
disrupting cell wall synthesis, 
specifically in the final cross-linking 
stage of the peptidoglycan layer.
Increase of Bacteroides, Blautia,  
Faecalibacterium, Parabacteroides— 
most probably due to high rate of  
resistance in these genera. Significant 
reduction of anaerobic population.
Perez-Cobas et al. 
(2013)
Monreal et al. (2005)
Morotomi et al. 
(2011)
Adamsson et al. 
(1999)
Lincosamides Clindamycin Bacteriostatic antimicrobial effect 
and protein synthesis mode of 
action.
Decreases in Bacteroides and Blautia. 
Increase in Enterobacteriaceae.
Perez-Cobas et al. 
(2013)
Fluoroquinolones Moxifloxacin, 
ciprofloxacin
Inhibition of DNA gyrase and 
topoisomerase IV. Fluoroquinolones 
sequester these enzymes into a 
drug/enzyme/DNA complex that 
holds double-stranded DNA breaks 
together, blocking replication.
Decrease in Faecalibacterium,  
Bacteroides, enterococci, enterobacteria.
Clostridia, Bifidobacteria,  
Lachnospiraceae, Ruminococcaceae, and 
Enterobacteriaceae.
Perez-Cobas et al. 
(2013)
Dethlefsen and  
Relman (2011)
Edlund et al. (2000)
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Antibiotic Class
Specific 
Antibiotic 
Examples Mode of Action Gut Microbiota Effects References
Polymyxins Colistin 
sulfomethate
Induces changes to the permeability 
of the cell wall by binding anionic 
lipopolysaccharide molecules and 
displacing calcium and magnesium, 
leading to cell leakage and death.
Orally administered colistin is poorly 
absorbed in the gut; therefore it has little 
effect on the intestinal microbiota.
WHO (2006)
Nitroimidazoles Metronidazole Entering cell in inactive state, 
becoming activated in the bacterial 
cytoplasm through electron transfer 
of the nitro group of the drug to a 
cytotoxic state with DNA-binding 
capabilities.
Active against anaerobic bacteria. 
Decreases in Firmicutes and Bacteroidetes 
and increases in Enterobacteriaceae.  
Metronidazole concentration appears low 
in feces; therefore intestinal microbiota 
effects are minimal.
Rea et al. (2010)
Sullivan et al. (2001)
Glycopeptides Vancomycin Interferes with glycosylation of 
the assembled peptidoglycan 
polymer after transport to the cell 
membrane.
Loss of C. leptum, C. coccoides, C. 
symbiosum, P. luminescens. Decrease in 
Firmicutes, Bacteroidetes, Clostridiaceae, 
Bacteroidaceae, Porphyromonadaceae, 
Clostridium, and Odoribacter.
Increase in Proteobacteria, Enterobacte-
riaceae, Streptococcaceae, Lactococcus, 
Sutterella, and Desulfovibrio.
Rea et al. (2011)
Yap et al. (2008)
Murphy et al. (2013)
Table 11.1 Summary of the Effects of Specific Antibiotic Classes on the Intestinal Microbiota—cont’d
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specifically the final cross-linking stage of the peptidoglycan layer (Page, 2012; 
Tipper, 1979; Strominger and Tipper, 1965). β-Lactams demonstrate broad-range 
activity against gram-negative and gram-positive bacteria (Holten and Onusko, 
2000). Discovered in 1928 by Alexander Fleming, in 1940 penicillin was the first 
antibiotic to be produced in a large scale and is accredited with having saved millions 
of wounded during World War II. However, before its discovery the first β-lactamase 
was identified in 1940 in E. coli (Abraham and Chain, 1940), which was countered 
by the first β-lactamase inhibitor (clavulanic acid) in 1976. Clavulanic acid, along 
with amoxicillin, now forms part of Augmentin (Foulstone and Reading, 1982). After 
the first β-lactamase there have been many challenges to the success of β-lactams. 
Carbapenemases, classified as either molecular class B (metallo-β-lactamases), A, 
or D (serine carbapenemases, also known as oxacillinases) form three of the four 
known classes of β-lactamases (Miriagou et al., 2010). The host of specific carbapen-
emases varies depending on class. Metallo-β-lactamases are disseminated mainly in 
P. aeruginosa, but also Acinetobacter baumanii, Enterobaceriaceae, and Klebsiella 
pneumonia (Queenan and Bush, 2007, Walsh, 2008). K. pneumonia is the most com-
mon host of class A carbapenems (Queenan and Bush, 2007), although there have 
been reports of its occurrence in other species such as Klebsiella oxytoca, Salmo-
nella enterica, E. coli, Enterobacter species, and Pseudomonas species (Queenan 
and Bush, 2007, Deshpande et al., 2006; Navon-Venezia et al., 2006; Villegas et al., 
2007; Bennett et al., 2009). Oxacillinases (class D) are common in A. baumanii 
(Queenan and Bush, 2007). Most recently, the emergence of New Delhi metallo-
β-lactamase-1 in 2008, which has since spread worldwide, has transformed mildly 
pathogenic bacteria into lethal MDR bacteria (Rolain et al., 2010). The prevalence 
of metallo-β-lactamases in P. aeruginosa is of significant clinical concern given 
the importance of P. aeruginosa in CF lung exacerbations. Metallo-β-lactamase– 
producing P. aeruginosa have shown an increase in the last 10 years and have been 
implicated in septicemia and pneumonia (Kouda et al., 2009; Gutiérrez et al., 2007; 
Pitout et al., 2007; Lagatolla et al., 2006). Extended spectrum β-lactamases (ESBLs) 
present another challenge to the treatment of gram-negative infections and are the 
main source of hospital- and community-acquired infections (Pitout and Laupland, 
2008). Mainly arising in Enterobacteriaceae such as E. coli and Klebsiella species, 
ESBLs have plasmid encoded capability of hydrolyzing the β-lactam ring of the oxy-
imino-cephalosporins (cefotaxime, ceftriaxone, and ceftazidime) and monobactams 
(aztreonam; Bush and Jacoby, 2010; Dortet et al., 2012). Cephamycins (cefoxitin) 
and carabapenems (imipenem and meropenem) retain their activity against ESBL-
producing bacteria. Reassuringly, in some cases β-lactamase inhibitors such as cla-
vulanic acid and tazobactam still have the ability to inhibit ESBLs (Bush and Jacoby, 
2010).
Bacteroides, Blautia, and Faecalibacterium species have been shown to increase 
in a study of four adults after a single antibiotic treatment with β-lactams such as 
ampicillin, amoxicillin, cefazolin, and sulbactam (Perez-Cobas et al., 2013; Monreal 
et al., 2005). This bacterial profile has been shown to be associated with bactericidal 
agents but not bacteriostatic antimicrobials. The increase seen in the Bacteroides 
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and Parabacteroides species may be explained by the presence of a high rate of 
β-lactamase-producing strains observed in these genera. In addition, high levels of 
cfiA gene identified suggest these strains act as reservoirs for antibiotic resistance 
genes and the common occurrence of cepA gene, which is responsible for production 
of cephalosporinases and penicillinases (Nakano et al., 2011; Wybo et al., 2007). 
Morotomi et al. (2011) also reported a dominance of Enterococcus genus after a 
single β-lactam antibiotic treatment. Adamsson et al. (1999) show that compared 
with a macrolide treatment (clarithromycin), a β-lactam treatment showed reduced, 
although still significant, ecological impact on the anaerobic populations and less 
emergence of resistant strains after treatment. The reduced disruption to anaerobic 
populations was also noted by Stark et al. (1993). In addition, Perez-Cobas et al. 
(2013) have demonstrated the metabolic effects of β-lactams in the alteration of bile 
acids, cholesterol, and hormones by intestinal bacteria. They showed a higher expres-
sion of genes related to energy metabolism during β-lactam treatment. This supports 
the hypothesis that long-term use of antibiotics undermines host-microbe mutualistic 
relationships.
Lincosamides
Clindamycin is a class of lincosamide antibiotics used to treat mainly anaerobic 
infections (Hedberg and Nord, 2002) with a bacteriostatic antimicrobial effect and a 
protein synthesis inhibitor mode of action. Resistance to clindamycin has increased 
significantly over the last two decades. Perez-Cobas et al. (2013) observed marked 
decreases in Bacteroides and Blautia genera immediately after administration; how-
ever, after 3 days a recovery of Bacteroides was observed, suggesting acquisition 
of resistance genes by these bacteria. They also noted that clindamycin induced an 
increase in Enterobacteriaceae compensating for loss of anaerobic bacteria. In com-
parison with other agents (fluoroquinolone or β-lactams) clindamycin was shown 
to result in a more variable and stronger effect on microbial community structure. 
Clindamycin has been shown to result in an increase in abundance of resistance 
genes, relative to other antibiotics such as moxifloxacin, amoxicillin, and cefazo-
lin/ampicillin/sulbactam combination, mostly of the efflux pump class (Perez-Cobas 
et al., 2013).
Fluoroquinolones
Fluoroquinolones inhibit bacterial cell proliferation by inhibiting DNA gyrase and 
topoisomerase IV, both essential enzymes in bacterial DNA transcription and replica-
tion (Hooper, 2001). In addition to inhibiting these two enzymes, fluoroquinolones 
sequester these enzymes into a drug/enzyme/DNA complex that holds double-
stranded DNA breaks together, blocking replication (Drlica, 1999). Treatment with 
different antibiotics from the fluoroquinolone class presents a similar initial response 
in the gut microbiota. Moxifloxacin showed a decrease in Faecalibacterium and Bac-
teroides, with ciprofloxacin showing similar effects with additional decreases seen 
in Lachnospiraceae and Ruminococcaceae (Perez-Cobas et al., 2013; Dethlefsen 
and Relman, 2011). Earlier fluoroquinolones such as ciprofloxacin, levofloxacin, 
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norofloxacin, and orofloxacin target aerobic bacteria, mainly gram negatives, but 
similar to moxifloxacin, a methoxyquinolone, they result in a reduction in numbers 
of Enterobacteriaceae. Moxifloxacin has a wider reaching activity than the others 
with activity against respiratory pathogens, including β-lactamase–producing aero-
bic gram-positive cocci; Haemophilus and Moraxella; aerobic gram negatives; and 
intracellular and atypical microorganism such as Legionella, Chlamydia, and Myco-
bacterium. Moxifloxacin also has activity against gram-positive and gram-negative 
anaerobes. In a study looking at the effects of repeated courses of oral ciprofloxacin 
(500 mg twice daily for 5 days at 2- and 8-month time points in a 10-month study) 
and the disturbance to the gut microbiota in three subjects, Dethlefsen and Relman 
(2011) showed an almost complete return to the pre-ciprofloxacin state after the first 
treatment; however, after a second treatment the microbiota community composition 
was different from what it had been at the start of the study and appeared to be stable 
in its new state. Edlund et al. (2000) also showed significant decreases of entero-
cocci, enterobacteria, bifidobacteria, and clostridia during moxifloxacin treatment 
(400 mg oral administration once daily for 7 days).
An interesting feature of fluoroquinolones is their ability to bind reversibly to 
bacteria and fecal material, resulting in reduced amounts of the drug in the intestine, 
translating to less disturbance of the total microbial intestinal population by fluoro-
quinolones (Edlund et al., 2000; Lidbeck et al., 1988). Because of this, moxifloxacin 
has a more targeted effect on the gut microbiota with more limited ecological distur-
bances (Edlund et al., 2000).
Polmyxins
Colistin sulfomethate is cyclopeptide, belonging to the family of polymyxins, 
which is produced by Bacillus polymyxa var. colistinus (Jeong et al., 2009; Storm 
et al., 1977). Colistin is mainly active against gram-negative organisms. Its mode 
of action involves inducing changes in the permeability of the cell wall by bind-
ing anionic lipopolysaccharide molecules and displacing calcium and magnesium, 
thus causing cell leakage and death (Jeong et al., 2009). Orally administered colis-
tin is known to be poorly absorbed in the gastrointestinal tract, and studies show 
that when excreted it is bound to the fecal material (Eichenwald and McCracken, 
1978). This may reduce the perturbation effect of the drug in vivo. Jeong et al. 
(2009) show that E. coli was the most susceptible to colistin. Colistin sulfometh-
ate is one of the most frequently used antibiotics for treatment of exacerbations 
in CF patients. Early eradication of Pseudomonas infection with nebulized drug, 
aggressive treatment of acute exacerbations with intravenous therapy, and long-
term suppressive maintenance therapy again nebulized are the three primary modes 
of usage in CF management. Colistin forms part of each of these (Littlewood et al., 
2000). P. aeruginosa is known to frequently develop resistance to β-lactam antibi-
otics and aminoglycosides. However, thus far in vitro resistance of Pseudomonas 
species to colistin is rare, cementing its place as a useful treatment for pseudo-
monal infections for the foreseeable future. Wright et al. (2013) have shown using 
in vitro culture methods that antibiotics (ceftazadime, colistin, azithromycin, and 
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tobramycin) at subinhibitory concentrations result in the phenotypic population 
diversification of P. aeruginosa. It is interesting to note that they demonstrated 
that ceftazadime and colistin contributed to more diversification than tobramycin 
and azithromycin. Diversification of the P. aeruginosa populations in the CF lung 
negatively affect antibiotic therapy success, leading to a chronic infection state 
and ultimately to progression of the disease. Whether this diversification pressure 
is also exerted on taxa in the gut has not been reported. Knowledge of differential 
diversification potential of antibiotics can contribute to more informed decisions 
for antibiotic selection in management and control of infection.
Nitrimidazoles
Metronidazole is the prototype of the nitroimidazole family and most widely used 
for treatment of anaerobic and protozoal infections (Lamp et al., 1999). Along with 
fidomoxacin and vancomycin, metronidazole is the mainstay of C. difficile treatment 
(Surawicz et al., 2013; Cornely et al., 2014), estimated to have colonized up to 50% 
of CF patients (Binkovitz et al., 1999; Bauer et al., 2014). Metronidazole is known to 
have activity against gram-negative (Bacteroides fragilis) and gram-positive (C. dif-
ficile) anaerobes (Lofmark et al., 2010). Metronidazole functions by entering the cell 
in its inactive or prodrug state, becoming activated in the bacterial cytoplasm through 
an electron transfer to the nitro group of the drug, or protozoa organelles, to a cyto-
toxic state with DNA-binding capabilities. Inhibition of DNA synthesis and DNA 
damage by oxidation leads to DNA degradation and cell death (Land and Johnson, 
1999; Diniz et al., 2000; Lofmark et al., 2010). Its activity is limited to anaerobic 
bacteria because aerobes lack the appropriate transfer proteins, conferring them with 
intrinsic resistance to metronidazole (Reysset, 1996). Mechanisms of resistance 
to metronidazole are primarily based on either decreased uptake of the prodrug or 
reduced electron transfer capabilities (Land and Johnson, 1999). Nitroimidazole (nim) 
resistance genes encode an alternative reductase protein that converts nitroimidazole 
to a nontoxic derivative, thus avoiding DNA damage (Reysset, 1996; Leiros et al., 
2004; Lofmark et al., 2010). Metronidazole resistance is generally low, although 
there have been reports of resistance in Sutterella species (Jousimies-Somer et al., 
2002). C. difficile maintains its susceptibility to metronidazole with no significant 
clinical resistance observed (Lofmark et al., 2010; Terhes et al., 2014). In a study 
using high-throughput sequencing, Rea et al. (2011) demonstrated phylum (reduc-
tion of Firmicutes and Bacteriodetes and increase of Proteobacteria) and family 
(increasing Enterobacteriaceae) effects of administering metronidazole in a colonic 
model experiment. The concentration of metronidazole in feces is low as a result of 
efficient absorption; therefore alterations to the normal microbiota after metronida-
zole treatment are minimal (Sullivan et al., 2001). Nagy and Foldes (1991) propose 
a mechanism of inactivation of metronidazole by intestinal enterococci, thus reduc-
ing its effect on the gastrointestinal microbiota. The success of oral metronidazole 
in Clostridium difficile infection (CDI) treatment is a result of the elevated plasma 
serum levels that diffuse through the damaged intestinal mucosa of infected individu-
als with greater efficiency (Sullivan et al., 2001).
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Glycopeptides
Glycopeptide antibiotics have an inhibitory mode of action on late-stage peptido-
glycan polymer synthesis. Glycopeptide antibiotics interfere with glycosylation 
of the assembled peptidoglycan polymer after transport to the cell membrane 
(Reynolds, 1989). Vancomycin, teicoplanin, and most recently telvancin are the only 
glycopeptide antibiotics approved by the US Food and Drug Administration (FDA; 
Van Bambeke et al., 2004, Damodaran and Madhan, 2011). Glycopeptides are active 
against most gram-positive organisms but few gram-negative organisms. Vancomy-
cin remains the first-line drug against methicillin-resistant Staphylococcus aureus 
(MRSA); however, emergence of resistance in enterococci and staphylococci has 
led to a restriction in the use of vancomycin as well as teicoplanin (Van Bambeke 
et al., 2004; Damodaran and Madhan, 2011). Yap and colleagues showed the dis-
turbance effect of vancomycin on the gut microbiota in mice using a 2 × 100 mg/kg 
per day dose for 2 days. Clostridium leptum, Clostridium coccoides, Cenarchaeum 
symbiosum, and Photorhabdus luminescens were lost immediately after treatment, 
with subsequent rapid recovery of C. leptum and C. coccoides. In an environmentally 
controlled 24-h model distal colonic experiment, Rea et al. (2011) showed a decrease 
in the major phyla, Firmicutes and Bacteroidetes, and an increase in Proteobacteria 
after addition of 90 μM vancomycin at eight hourly intervals. The rapid proliferation 
of Enterobacteriaceae at the expense of other gram negatives and Firmicutes dur-
ing vancomycin treatment is reported (Rea et al., 2011; Yap et al., 2008). In a diet-
induced obesity mouse model administering 2 mg/day vancomycin for 20 weeks, 
Murphy et al. (2013) attributed the decrease in Firmicutes and Bacteroidetes at the 
phylum level to a decrease in Clostridaceae and Bacteroidaceae at the family level, 
respectively, and increasing Proteobacteriaceae was attributed to increasing Entero-
bacteriaceae. At the family level they also noted decreases in Porphyromonadaeae 
and increases in Streptococcaceae and Desulfovibrionaceae, whereas at the genus 
level increases in Lactococcus, Sutterella, and Desulfovibrio and decreases in Clos-
tridium and Odoribacter were observed.
Effects of Combination Therapy on Gut Microbiota
Combination or multidrug therapy often confers advantages over single drug therapy 
in terms of a wider range of targets, synergistic effects, reduction of MDR organisms, 
and reduction in total amount of antibiotic used; however, it incurs high costs, compli-
cations for administration, and drug-related toxicity (Elphick and Tan, 2005; Perron 
et al., 2012; Gould and van der Meer, 2007). Taylor et al. (1993) reported that 80% 
of clinics had preference for combination therapy. Combinational antibiotic therapy 
poses challenges to identifying, quantifying, and comparing the specific effects of anti-
biotic classes on the gut microbiota. At present, treatment of P. aeruginosa infection 
in patients with CF involves two to three antibiotics, demonstrating improved synergy 
(Zebouh et al., 2008; Hewer and Smyth, 2014). In general, this may include the use 
of inhaled antibiotics such as tobramycin and colistin (Littlewood and Macdonald, 
1987, Ratjen et al., 2001), oral quinolones such as ciprofloxacin (Taccetti et al., 2005), 
and intravenous antibiotics usually involving a β-lactam antibiotic in combination 
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with an aminoglycoside antibiotic (Döring et al., 2000, Hewer and Smyth, 2014). 
Combination therapies are a commonly used approach for biofilm management, with 
the rationale that multiple antibiotics, with a range of individual targets can combine 
to help suppress or eradicate the varying antagonistic phenotypes present in the bio-
film (Barraud et al., 2013). Colistin is known to be active against bacterial cells with 
low metabolic activity whereas tetracycline and ciprofloxacin are known to be active 
against metabolically active cells (Pamp et al., 2008; Herrman et al., 2010).
Conclusive results yielding specific guidelines for treatment of pulmonary exac-
erbations and delaying chronic P. aeruginosa infection in CF patients have yet to be 
reached on whether combinational or monotherapy is more effective because of a 
lack of studies testing combinational therapy options versus monotherapy in a head-
to-head manner with control for confounding factors. Of the studies available, it is 
difficult to unequivocally indicate which is the most effective because studies differ 
in length of administration of antibiotic, age, health status and history of patient 
cohort; differing times from detection to initiation of treatment; frequency of sur-
veillance; markers of success; and statistical analysis. However, the current physi-
cian consensus infers a preference for combinational therapy for patients with CF 
(Elphick and Tan, 2005).
LONG-TERM ISSUES OF CHRONIC ANTIBIOTIC USE
MULTIDRUG RESISTANCE
Almost immediately after the introduction of the first antibiotics, a parallel emergence 
of resistance has inhibited their success (Davies and Davies, 2010). Most recently, 
a World Health Organization report on antimicrobial resistance (AMR) (2014) 
warns of the dangers of entering a postantibiotic era in which minor infections could 
emerge as life threatening diseases in the face of an AMR pandemic. MDR is a major 
public health issue facing the medical and wider community (Laxminarayan et al., 
2013). In the European Union (EU), AMR is estimated to be responsible for 25,000 
deaths each year, whereas health-care–related costs are estimated to be €0.9 billion 
with a further €1.5 billion expenditure on productivity losses (Rodier, 2011; Report 
EEJT, 2009). MDR is compromising our ability to manage infectious disease. Well- 
documented MDR organisms include P. aeruginosa and Burkholderia cepacia 
complex, as well as emerging methicillin-resistant Stenotrophmonas maltophilia 
and MRSA. MDR was responsible for 23,000 deaths in the United States in 2013, 
of which MRSA and Streptococcus pneumoniae were responsible for 11,000 and 
7000 deaths, respectively (CDC, 2013). Antibiotic overuse and misuse is the driv-
ing force of the development of resistant organisms (Laxminarayan and Heymann, 
2012). An empirical strategy of treatment based on expert consensus remains the 
mode of action on diagnosis of pulmonary exacerbation. This generalized treatment 
strategy inevitably contributes to the adverse effects of antibiotic overuse in terms of 
dose and time. This is compounded by the increase in age of the CF demographic 
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(Waters and Ratjen, 2006) globally (CFRI Annual report 2011; Davis, 2006; www.
cff.org), with the ratio of adult CF patients to pediatrics increasing each year.
The human gastrointestinal tract is an environment where 1013–1014 microorgan-
isms are in constant interaction, providing an ideal situation for rapid dissemination 
of resistance genes between commensals and pathogens (Salyers et al., 2004; Davies, 
1994). The human gut microbiota is now viewed as a reservoir where commensals and 
pathogens are in direct contact, thus facilitating the spread of resistance genes (Salyers 
et al., 2004; Sommer et al., 2009; Fouhy et al., 2014). Studies have established that the 
gut resistome is established in infancy, even in the absence of antibiotic therapy, grow-
ing and diversifying with age (Fouhy et al., 2014). In response to antibiotic therapy, 
resistance genes are expressed and selected, with strains carrying resistance prolifer-
ating, amplifying the resistance reservoir (Lu et al., 2014; Fouhy et al., 2014). In CF 
patients, or other groups on chronic antibiotic therapy, the resistome is likely to have 
increased capabilities. Whole genome sequencing has shown that lateral gene transfer 
and mobilizable elements that incorporate into various host bacteria are responsible 
for most resistance (Ochman et al., 2000). Transferable resistance genes may arise in 
commensals and through lateral gene transfer mechanisms spread to clinically relevant 
pathogenic strains. It is postulated that the gut microbiome may facilitate the acquisi-
tion of resistance by pathogenic strains (Sommer et al., 2009). Sommer et al. (2009) 
used a functional metagenomic approach to characterize the antibiotic resistome of 
two healthy unrelated humans who had not been treated with antibiotics for a least 
1 year. Phylogenetic profiling of aerobically cultured strains from the gut microbi-
ome showed they were primarily members of the Proteobacteria phyla and to a lesser 
extent Firmicutes and Actinobacteria. Resistance genes belonging to one of the fol-
lowing classes—tetracycline efflux pumps, two classes of aminoglycoside-modifying 
enzymes, and three classes of β-lactam–inactivating enzymes (TEM, AmpC, and CTX-
M)—were detected. Characterizing the human gut resistome may increase understand-
ing of the origin of the antibiotic resistance, ultimately addressing the MDR issue.
The expression and subsequent persistence of resistance genes ensuing antibiotic 
treatment varies depending on antibiotic class, duration, and dose strength of treat-
ment. Persistence of resistance may be observed years after an antibiotic course. 
For instance, after a 5-day antibiotic treatment (500 mg twice daily) with ciprofloxa-
cin, initial gut microbiota perturbations recover; however, resistance to the particu-
lar antibiotic is enriched and may be observed for months or even years afterwards 
(Dethlefsen et al., 2008). Likewise, Sjölund et al. (2003) showed that in three of five 
patients post-clarithromycin treatment, erythromycin resistance was present after 1 
year and in one patient after 3 years. Jernberg et al. (2007) also showed the persis-
tence of resistance genes (ermF, ermG, and ermB) after clindamycin treatment up 
to 2 years after a 7-day antibiotic treatment. Shoemaker et al. (2001) demonstrated 
that the presence of the tetQ gene has increased from 30% to 80% in all strains of 
Bacteroides as a result of conjugal gene transfer in the last three decades.
Some genera may contribute to multidrug resistance more than others by acting 
as a reservoir for mobilizable resistance determinants. Bacteroides and Parabac-
teroides species are mutualistic inhabitants of the gut performing many beneficial 
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functions for the host, such as carbohydrate metabolism (Xu et al., 2003). Bacte-
roides form 25% of the adult human gut microbiota (Salyers, 1984) and have been 
implicated in many opportunistic infections, particularly B. fragilis (Wexler, 2007; 
Cao et al., 2014). They have an innate ability to produce β-lactamases such as cepha-
losporinases and penicillinases encoded by the cepA gene (Gutacker et al., 2000). 
Clindamycin resistance, encoded by the ermF, ermB or ermG genes or through efflux 
pumps, in Bacteriodales ranges from 10% to 42% and confers protection against 
macrolides, lincosamides, and stretogramin B (Wybo et al., 2007; Gupta et al., 2003; 
Nakano et al., 2011; Shoemaker et al., 2001; Pumbwe et al., 2007). In a study by 
Nakano and colleagues (2011), 53.5% of tested Bacteroides and Parabacteroides 
strains were tetracycline resistant, primarily because of the acquisition of the tetQ 
ribosome protection protein. The rise of resistance genes in predominating and 
functionally vital genera of the human gastrointestinal tract provide pathogens with 
increased opportunity for acquisition of many resistance determinants.
AMR rates are increasing and studies such as the SMART (Study for Monitoring 
Antimicrobial Resistance Trends), PROTEKT (Prospective Resistant Organism Track-
ing and Epidemiology for the Ketolide Telithromycin), and SENTRY (an international, 
longitudinal study on the susceptibility of pathogens sponsored by Bristol Meyers 
Squibb) seek to globally monitor and characterize AMR rates (Morrissey et al., 2013). 
The SMART study describes the increase in prevalence of ESBLs, conferring resistance 
to β-lactams, in Asia, Europe, Latin America, Middle East, North America, and the South 
Pacific. The study also reports the increasing resistance to fluoroquinolones, particularly 
in P. aeruginosa (increases from 22% to 33% were seen in North America). Macrolide 
resistance rates have also been shown to be increasing (Cresti et al., 2002). Recent stud-
ies have indicated this is due to the epidemic spread of ermB resistance genes among 
streptococcal populations and in particular Streptococcus pyrogenes, either by horizontal 
gene transfer or clonal expansion of resistant isolates after selective pressures of antibi-
otic treatment (Jakobsson et al., 2010). Sjölund et al. (2003) have reported the presence 
of macrolide-resistant enterococci after selection by clarithromycin and metronidazole.
Development of Opportunistic Pathogens and Antibiotic-Associated 
Diarrhea
Chronic antibiotic therapy results in significant alterations in the gut microbiota, creat-
ing opportunities for opportunistic pathogens, primarily C. difficile, to establish and 
proliferate. C. difficile is mostly a nosocomical infection of the elderly, but it can 
also be community acquired, affecting younger populations and adults. The CDC has 
linked C. difficile to 14,000 deaths in America (CDC, 2013). The European Center for 
Disease Control estimates that CDI costs the EU €3 billion per year (ECDC, 2015). 
Broad-spectrum antibiotic therapy has been associated with increased incidence 
of C. difficile and is identified as one of the most well-recognized risk factors for 
C. difficile and indeed recurrent and refractory CDI (Bartlett and Gerding, 2008; Diggs 
and Surawicz, 2009). Broad-spectrum antibiotics induce a dysbiotic gut microbiota, 
particularly among anaerobic populations, providing C. difficile with an opportunity 
to proliferate. Indeed, Owens et al. (2008) reported 94% of hospitalized patients with 
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CDI had received antibiotics before or during their hospital stay. C. difficile is respon-
sible for 20–25% of AAD cases and 90–100% of pseudomembraneous colitis (Rea 
et al., 2010; Cramer et al., 2008). Ironically, antibiotic treatment of CDI perpetuates 
its proliferation, increasing strains resistant to vancomycin, particularly enterococci 
(Chang et al., 2008), lowering diversity and providing C. difficile with opportunity to 
proliferate. The association between ampicillin, cephalosporins, and fluoroquinolones 
and CDI is well recognized in the literature (Gerding, 2004; Sullivan et al., 2001). It 
is interesting to note that the emergence of particular antibiotics as risk factors for 
CDI has paralleled the frequency of that particular antibiotic class in general medi-
cal use. The increase of CDI was initially associated with clindamycin, which is the 
preferential treatment for various anaerobic, streptococcal, and Staphylococcus infec-
tions. Since the 1990s, the increase in the use of fluoroquinolones to treat various 
infections has precipitated these antibiotics in becoming risk factors for CDI and has 
contributed to the emergence of hypervirulent strains such as ribotype 027, which is 
characterized by fluoroquinolone resistance, binary toxin production, and increased 
toxin production due to a mutation in the tcdC gene (Pepin et al., 2005; Kuijper et al., 
2008). Metronidazole and vancomycin have also been determined as risk factors for 
CDI. In cases in which antibiotics are necessary to treat concomitant infection, alter-
native antibiotics to those identified as CDI development risk factors should be used 
where possible. As expected, increased duration of antibiotic courses and antibiotic 
combination therapy are associated with increased risk of CDI (Owens et al., 2008). 
Not all antibiotics for CDI infection are associated with increased risk. Piperacillin 
in combination with tazobactam has shown considerable success in treatment of CDI 
but with less associated risk of increased development of infection or relapse (Owen 
et al., 2008). Vancomycin and, more recently, fidaxomicin (2011) are the only drugs 
approved by the FDA for CDI treatment. Fidaxomicin is particularly effective in treat-
ing recurrent CDI because it has less impact on the fecal microbiota, translating into 
a more resilient microbial assemblage after treatment. Fidaxomicin shows less risk of 
development of resistance than vancomycin in in vitro studies (Zar et al., 2007). Alter-
native therapies that may facilitate the reduction of antibiotics are necessary to treat 
CDI. These include fecal microbial transplant (FMT), which is an alternative therapy 
at conceptual stage with early pioneering case studies showing considerable success in 
patients with reoccurring symptomatic C. difficile (Petrof et al., 2013; Koenigsknecht 
and Young, 2013). Another alternative includes thuricin CD, a novel antimicrobial 
peptide (AMP) or bacteriocin produced by Bacillus thuringiensis, which has been 
patented as a CDI therapy (Rea et al., 2010). The potency of thuricin CD has been 
shown to be greater than vancomycin and in some cases greater than metronidazole. In 
addition, thuricin CD shows no antimicrobial activity against a range of commercially 
available probiotics, demonstrating its narrow substrate range (Rea et al., 2011).
Asymptomatic carriage of C. difficile in CF is well recognized; however, the 
mechanisms of protection against infection, but not colonization, are not fully under-
stood. Carriage rates in healthy adults vary from 0% to 15% (Viscidi et al., 1981; 
Nakamura et al., 1981), compared with up to 50% in CF cohorts—a result of pro-
phylaxis and frequent hospitalizations. However, unlike normal populations in which 
 Long-Term Issues of Chronic Antibiotic Use 241
approximately 50% of colonized individuals develop CDI, or in more severe cases 
pseudomembranous colitis, development of response to C. difficile toxins is rare in 
CF patients (Kyne et al., 2000; Peach et al., 1986; Welkon et al., 1985). It is hypoth-
esized that the unique microbial assemblage of CF patients with high levels of Enter-
bacteriaceae, lactobacilli, Pseudomonas, and Staphylococcus confers protection 
and resistance against C. difficile growth, but not colonization (Rolfe et al., 1981). 
Welkon et al. (1985) suggest an altered gut pH as a result of defective ion transport 
inhibits toxin production or degrades toxins, although there is no evidence to support 
this. Another possibility postulates that exposure to C. difficile at such an early age 
mediates an immune response that protects in later life (Welkon et al., 1985). The 
relatively low incidence of CDI despite high rates of toxigenic C. difficile coloniza-
tion and antibiotic usage is an area of much needed research.
Metagenomic studies in cohorts with Clostridium difficile-associated diarrhea 
(CDAD) that have investigated microbiome shifts noted increases in C. difficile and 
Bacteroidetes, C. coccoides, Eubacterium rectale, Ruminococcus gnavus, and Clos-
tridium nexile (Chang et al., 2008). It is interesting to note that the Bacteroidetes 
phylum seems to show a strong association with CDAD in several studies. Manges 
et al. (2010) show that low levels of Bacteroidetes are associated with CDAD. Tvede 
and Rask-Madsen (1989) demonstrate using bacteriotherapy experiments that the 
absence of Bacteroides species such as Bacteroides ovatus, Bacteroides vulgaricus, 
and Bacteroides thetaiotaomicron may result in recurring CDI whereas their abun-
dance in the gut microbiota may afford protection against colonization and prolifera-
tion against C. difficile. Low Firmicutes and Bacteroides ratios, along with increasing 
facultative anaerobes, have been shown to be associated with C. difficile colonization 
in infants (Rousseau et al., 2011). Metagenomic studies of patients with CDI noted a 
decrease in alpha diversity at the DNA level (Chang et al., 2008; Knecht et al., 2014). 
However, Knecht et al. hypothesize that instead of a microbiota-wide compositional 
change, a loss of functionality of a single species may impair the resilience of the 
microbiota to C. difficile colonization. These functions may include short-chain fatty 
acids (SCFAs) or antimicrobial production, which may protect against C. difficile 
proliferation. Recent research by Knecht et al. (2014) indicates that Lachnospiraceae 
may be one such species in which low or high levels are associated with protection 
against or colonization with C. difficile.
Antibiotic substitutions for other options with less risk of CDI development asso-
ciated may be effective (Vonberg et al., 2008). Further research into drug develop-
ment is warranted to provide options that cause less disruption to the microbiota, 
consequently affording C. difficile less opportunity to proliferate.
Interference of Mutualistic Host–Microbe Interactions through Antibiotic-
Induced Alteration of Gut Microbiome
The human intestinal microbiota develops a partnership with the host and is essential 
to health and functions such as nutrition, immunoregulation, metabolism, develop-
ment, and pathogen resistance. With approximately 100 times more genes than the 
human genome, the gut microbiome lends us functional features we have not had to 
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evolve ourselves (Backhed et al., 2005). Although the intestinal community does seem 
to have a level of taxonomic functional redundancy, antibiotic-mediated elimination 
or significant reduction of important members of the microbiota is likely to affect 
functionality and host physiology, particularly in the case of chronic antibiotic therapy 
(Perez-Cobas et al., 2013). Many key species of the human intestinal microbiota per-
form important functions; however, disruption of the core gut colonizers by antibi-
otic therapy may have a more profound effect on the functioning of the microbiota as 
a symbiotic partner of the host. Examples include B. thetaiotaomicron, a prominent 
mutualist in the intestinal microbiome, which has a genome-encoded capacity for car-
bohydrate metabolism far greater than the carbohydrate-metabolizing capabilities of 
our human genome (Shipman et al., 2000; Backhed et al., 2005). The gut microbiota 
also functions in regulation of bile acid and choline metabolism. The gut microbiota 
ecosystem comprises a dynamic network of functional interactions. As in any ecosys-
tem, even targeted, or narrow-spectrum antibiotic effects will influence not only the 
target but also indirectly affect many interaction partners (Willing et al., 2011). Anti-
biotic therapy can induce host immunity effects through the loss of bacterial ligands, 
metabolites, and specific bacterial signals (Willing et al., 2011). Receptors involved 
in host immunity, such as toll-like receptors and NOD-like receptors are activated by 
specific bacterial ligands such as lipopolysaccarhide, lipoteichoic acid, flagellin, and 
peptidoglycan. The loss of specific bacterial ligands reduces immune signals (Wells 
et al., 2011). Metabolic profiles of antibiotic-treated mice show a reduction of SCFAs, 
with downstream reduction in the antiinflammatory effects of SCFAs as well as func-
tions in regulation of cell proliferation, differentiation, growth, apoptosis, vasodilation, 
and wound healing (Yap et al., 2008; Millard et al., 2002; Leung et al., 2009; Bergman, 
1990). Populations of bacteria have specific signals associated with them that may be 
lost after antibiotic treatment. In addition, many studies report reduced expression and 
secretion of AMPs, directly affecting first-line microbial defense (Meyer-Hoffert et al., 
2008). Taken together, these factors result in a host more susceptible to pathogen insult 
(Willing et al., 2011).
The diversity of the human gut microbiota is the result of natural selection at the 
microbial level and the host level (Backhed et al., 2005). Diversity confers resilience 
to stress, such as antibiotic therapy, by harboring a diverse range of responses. This 
is known as the insurance hypothesis (Guarner, 2007). In general, low diversity cor-
relates with poor health status (Lozupone et al., 2012; Claesson et al., 2012). This is 
one of the primary caveats of gut health and is demonstrated in infants, adults, and 
elderly populations. Many disease states have been associated with low-diversity 
microbiota signatures in recent years. Antibiotics as agents drive the microbiota to an 
altered assemblage through a gradual drift or dramatic shift, which may lead to the 
onset of microbiota-related diseases associated with less diversity, such as obesity 
(Turnbaugh et al., 2006), diabetes (Larsen et al., 2010), and inflammatory bowel 
disease (IBD; Dicksved et al., 2008). Turnbaugh et al. (2006) demonstrated that colo-
nization of germ-free mice with “obese” microbiota resulted in development of obese 
phenotype and likewise in lean mice. Childhood antibiotic use and the resulting 
altered microbiota are potentially associated with asthma, atopic disease and obesity 
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(Marra et al., 2006; Noverr and Huffnagle, 2005). Low gut microbiota diversity in 
infants has been associated with eczema (Abrahamsson et al., 2012), particularly 
of the phylum Bacteroidetes and its genus Bacteroides. Indeed, in a study of 123 
CF children, 59% presented with skin hypersensitivity allergy (Warner et al., 1976). 
Although not proposed by the authors at the time, low-diversity gut microbiota may 
have contributed to the hypersensitivity observed. The reduction of gut microbiota 
diversity after exposure to antibiotics is well documented. Antibiotic exposure may 
reduce overall diversity and/or diversity of select taxonomic groups, as seen by Jern-
berg et al. (2007) in a study of four patients exposed to 150 mg clindamycin 4 times 
daily. They observed an overall reduction in gut microbiota diversity but also a reduc-
tion in diversity of the Bacteroides community and emergence of clindamycin-resis-
tant strains. In a study investigating the effects of ciprofloxacin (500 mg twice daily 
for 5 days) on the gut microbiota of adult patients, the abundance of one-third of bac-
terial taxa were reduced (Dethlefsen and Relman, 2011). Likewise, Rea et al. (2010) 
showed reduction of diversity after exposure to metronidazole and vancomycin in a 
human colonic model, mostly accounted for by the proportional increase of Entero-
bacteriaceae. However, despite the well-acknowledged effect of the lack of diversity 
on host health, the functional redundancy and resilience of the gut microbiota is also 
accepted. Indeed, Dethlefsen et al. (2008) have demonstrated that although the gut 
microbiota was disturbed after treatment with ciprofloxacin, they observed a conti-
nuity of microbial functions. It remains to be investigated whether the low-diversity 
microbiota disorders described could be the result of perturbations brought about by 
antibiotics alone or a combination of factors in which antibiotic therapy is perhaps 
the factor that tips the balance to a disease state.
The hygiene hypothesis is quoted frequently as an argument against sterilizing 
our environment and indeed our bodies through antibiotic use (Wills-Karp et al., 
2001). The increasing incidence of autoimmune disorders such as asthma, eczema, 
celiac disease, and IBD may be related to disruption of normal host–microbe inter-
actions by antibiotics (Guarner et al., 2006). Guarner hypothesizes that deficient 
exposure to mutualistic bacteria such as bifidobacteria and lactobacilli explains the 
increase of immunodysregulatory disorders in modern society. Guarner proposes the 
use of prebiotics and probiotics as a more favorable method of infection control.
MODULATION OF THE GUT MICROBIOTA
DIET
Diet has rapid and profound modulatory effects on the gut microbiota composition 
and functionality. Various diet types, including high-fat, high-sugar, “Western,” and 
low-fat, polysaccharide-rich diets, have been associated with microbiota signatures 
differing at the compositional and functional gene level. Particular bacterial species 
have genetically encoded specific metabolic capabilities. The gut microbiota adapts to 
dietary intake to select bacterial populations with the genetic capabilities best suited 
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for metabolism substrates of a given diet (Scott et al., 2008; Power et al., 2014). The 
rapid response of the gut microbiota to changes in diet has been demonstrated by 
studies in conventionalized germ-free mice. A change from a low-fat/plant-rich diet 
to a high fat and sugar/low plant polysaccharides “Western diet” showed changes in 
the gut microbiota within a single day, with increases in Firmicutes and decreases 
in Bacteroidetes (Turnbaugh et al., 2009). Hildebrandt et al. (2009) showed a simi-
lar rapid response in the gut microbiota to a dietary change (high-fat/low-fiber or 
low-fat/high-fiber) within 24 h. Most pertinent to CF are the effects of a high-fat 
diet on the gut microbiota composition. Dietary requirements for CF persons include 
120–150% estimated average requirement of energy and 200% reference nutrient 
intake for protein (Littlewood and Macdonald., 1987; Pencharz and Durie., 1993). 
In addition, it is recommended that the CF total calorie intake should comprise 40% 
fat (White et al., 2004). The response of the gut microbiota to dietary fat is well 
documented. De Filippo et al. (2010) established the profound difference between 
the gut microbiota of European children on a typical Western diet (high fat, sugar, 
animal protein, and starch and low fiber content) and children in the African state 
of Burkina Faso, who consumed a predominantly vegetarian diet that was high in 
plant polysaccharides, starch, and fiber and low in animal protein and sugar. The 
Burkina Faso children had a lower abundance of Firmicutes and a higher abundance 
of Bacteroidetes genera (Xylanibacter and Prevotella), involving cellulose and xylan 
hydrolysis, enabling efficient energy extraction from their plant-rich diet. Indeed, a 
study by Wu et al. (2011) linked gut microbial enterotypes dominated by either Bac-
teroides or Prevotella with diets dominated by either protein and animal fat or carbo-
hydrates along with low meat and dairy intake, respectively. A high-fat diet has been 
shown to influence a less diverse microbiota and a higher proportion of Bacteroide-
tes, Parabacteroides, Eubacterium, Anaerotruncus, Lactonifactor, and Coprobacil-
lus in elderly subjects (Claesson et al., 2012). In the same study, community-dwelling 
subjects having a predominantly low to moderate fat intake had higher abundance 
of Prevotella, Coprococcus, and Roseburia. In addition to compositional microbial 
effects, a high-fat diet has been shown to result in a low-grade intestinal inflamma-
tory state, which is a hallmark of CF (Arkan et al., 2005; Werlin et al., 2010).
Gastrointestinal manifestations of CF include exocrine pancreatic insufficiency 
(PI), steatorrhoea, intestinal inflammation, distal intestinal obstruction syndrome 
(DIOS) and cystic fibrosis–related diabetes (CFRD). PI occurs in 90% of CF patients, 
resulting in malabsorption of fat; protein; and fat-soluble vitamins A, D, E, and K and 
subsequent malnutrition (Fieker et al., 2011; Dodge and Turck, 2006). Undigested, 
unabsorbed dietary fat is excreted in stools, known as steatorrhoea (Somaraju and 
Solis-Moya, 2014) PI predisposes CF individuals to the onset of DIOS, an obstruc-
tion of fecal transit at the ileocecal junction (Somaraju and Solis-Moya, 2014). DIOS 
occurs in 10–20% of patients because of increased water absorption as a result of 
defective intestinal CFTR. CFRD occurs in approximately 2% of children, 19% of 
adolescents, and 40–50% of adults presenting with CF. CFRD, distinct from the type 
I and type II diabetes found in the general population (Stecenko and Moran, 2010) is 
associated with poorer pulmonary function and nutritional status (Koch et al., 2001; 
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Marshall et al., 2005). Although there is a paucity of information on how these gas-
trointestinal manifestations affect the intestinal microbiota, especially in the CF con-
text, a microbiota response to such comorbidities is probable.
Positive Modulation of the Gut Microbiota
Positive modulation of the gut microbiota and host health can be achieved using pro-
biotics, most commonly Lactobacillus or Bifidobacterium species. The beneficial 
effects of probiotics are perhaps more subtle than previously thought. Scientists are 
moving from a theory that probiotics alter total gut microbiome composition to a con-
cept of prebiotics conferring a direct health benefit on the host (Power et al., 2014; 
Ouwehand et al., 2002). Thus far probiotics have been demonstrated to have thera-
peutic potential in treatment of AAD (Videlock and Cremonini, 2012; Hempel et al., 
2012), CDI (Na and Kelly, 2011), IBD (Isaacs and Herfarth, 2008), and irritable bowel 
syndrome (Andersen and Baumgart, 2006). There have been preliminary but promis-
ing studies trialing administration of Lactobacillus rhamnosus GG (LGG) as a pro-
biotic in pediatric CF cohorts. Bruzzese et al. (2004, 2014) showed the success of 
LGG in reducing intestinal inflammation as indicated by the noninvasive inflammatory 
markers nitric oxide and fecal calprotectin. The treated cohort also reported decreased 
abdominal pain. To further investigate the positive effects of LGG for the CF popula-
tion, Bruzzese et al. (2007) investigated the effects of LGG administration on the rate 
of pulmonary exacerbation. They demonstrated a protective effect of LGG in children 
chronically infected with Pseudomonas and consequently a reduction in pulmonary 
exacerbations and increase in FEV1. Weiss et al. (2010) showed a significant reduc-
tion in pulmonary exacerbations in children with CF infected with P. aeruginosa after 
administration of a probiotic cocktail containing Lactobacillus acidophilus, Lactoba-
cillus bulgaricus, Bifidobacterium bifidum, and Streptococcus thermophilus; 90% of 
patients were also receiving azithromycin treatment at the time. The offsite effects of 
Lactobacillus species on Pseudomonas in the lung suggest a direct effect between the 
former and the latter, supported by earlier studies in mice in which LGG administration 
reduced Pseudomonas species, and Lactobacillus plantarum showed inhibitory activ-
ity toward Pseudomonas species (Valdez et al., 2005). Bruzzese et al. (2014) showed 
partial recovery of gut microbiota in CF children on antibiotic treatment who were 
subsequently treated with LGG with a significant increase of Bacteroides and a trend 
toward an increase in F. prausnitzii, a known antiinflammatory agent.
Probiotic strains with antibiotic tolerance may have application after or during anti-
biotic therapy. However, antibiotic tolerance in probiotic bacteria is generally associ-
ated with safety concerns by food safety authorities such as the European Food Safety 
Authority (EFSA) because of the risk of dissemination of resistance determinants from 
probiotics to commensal or pathogenic members of the gastrointestinal microbiota. 
Plasmid or mobile genetic element mediated resistance carried by many probiotic 
genera poses a serious safety issue (Sharma and Singh Saharan, 2014). In addition, 
there are issues for antibiotic–probiotic combination therapy and possible resulting 
antagonistic relationships that may exist. Increased bacterial load due to the presence 
of viable probiotics may reduce the potency of antibiotics. It has been shown that 
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the potency of vancomycin decreases depending on the numbers of bacteria exposed 
(Udekwu et al., 2009). Probiotic-antibiotic combinations that preserve the potency 
of the antibiotic and the viability of the probiotic must be selected (Hammad and 
Shimamoto, 2010). Antibiotic-tolerant probiotic therapies remain at the conceptual 
stage because of difficulty in determining safety. However, the potential for application 
in a cohort with chronic antibiotic usage warrants further research into this novel area.
Knowledge of which microbiota community composition resists change more 
efficiently may be important in probiotic development. It may be possible to direct 
microbial communities toward a more resilient assemblage in individuals for whom 
chronic antibiotic use is necessary. In the future, probiotics may provide an adjunct 
therapy along with antibiotics for the treatment of CF symptoms. The possibility of 
reduction of antibiotics through use of alternative therapies, such as probiotics, is 
attractive to patients and clinicians.
FUTURE DIRECTIONS
Antimicrobial discovery has been in decline since the 1970s, and MDR is an increas-
ingly serious threat to global public health. As an immediate response to MDR we can 
curb the inappropriate use and overuse of antibiotics, gain knowledge on antibiotic 
effects, and administer at doses that target aberrant bacteria while beneficial bacteria 
are preserved, all of which can help preserve and maintain the effectiveness of antibiot-
ics for the next generation. In this age of high-throughput, next-generation sequenc-
ing technologies, it is imperative that we use the technologies available to us to tailor 
the antibiotics currently available to the individual instead of the “catch-all” broad-
spectrum approach that has consequences on our antibiotic resources. CFMATTERS 
(Cystic Fibrosis Microbiome Derived Antimicrobial Therapy Trial in Exacerbations 
Results Stratified) is an EU-funded multicenter study currently examining this ques-
tion in adult patients with CF (www.cfmatters.eu, https://clinicaltrials.gov/ct2/show/
NCT02526004). Alternative additional strategies dealing with infection need to be 
brought from the bench to mainstream clinical practice. There have been several studies 
investigating the use of bacteriophage as a therapeutic to treat CF lung infection, par-
ticularly in treating Pseudmonas infection, but also S. aureus and B. cepacia (Brussow, 
2012; Debarbieux et al., 2010; Alemayehu et al., 2012, Morello et al., 2011). Phage 
therapy is advantageous over antibiotic therapy because of its specificity to the target 
pathogen, its ability to replicate at the site of infection, and its ability to evolve along 
with bacterial populations that may develop resistance. Alemayehu et al. (2012) have 
demonstrated the efficacy of a phage cocktail (a myovirus (ϕNH-4) and a podovirus 
(ϕMR299-2)) to clear murine Pseudomonas lung infection. Furthermore, it has been 
shown that phage not only cleared Pseudomonas infection but also prevented infection 
when administered 24 h before infection, highlighting a potential role of phage in pro-
phylaxis (Debarbieux et al., 2010; Morello et al., 2011).
Inhibition of Pseudomonas virulence and biofilm formation through disabling 
quorum sensing networks is another potential therapeutic approach for infection 
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control. O’Loughlin et al. (2013) have demonstrated the utility of a quorum sensing 
inhibitory molecule (meta-bromo-thiolactone) to block pathogenesis by interacting 
with the two major quorum sensing systems Lux I/R. In addition they demonstrated 
the potential for preventative and curative treatment using meta-bromo-thiolactone. 
Further work is needed in these areas.
CONCLUSION
The collateral consequences of antibiotic therapy on the gut microbiota have been 
widely studied, and it is accepted that chronic and/or long-term antibiotic use has com-
positional and potentially functional effects on the gut microbiota. In a cohort with 
chronic antibiotic usage, such as CF, antibiotic resistance capabilities are expected to 
be high with consequences for subsequent antibiotic therapy. The long-term persistence 
of resistance genes in the gut microbiota in response to antibiotic therapy poses a con-
cern for the clinical management of infection. Moving forward, tailored, individualized 
antibiotic strategies may prove critical along with additional options other than antibi-
otics. Phage therapy and targeting of quorum sensing networks may provide alterna-
tives or adjunct therapies to antibiotic therapy in the future. Probiotics may be used as 
restorative agents to reintroduce depleted populations and maintain the gut microbiota 
ecosystem. In the interim, the medical community and wider society must endeavor to 
preserve our antibiotic resources through strategic and rational administration.
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